Amgen, Watson Aim To Launch First Joint Oncology Biosimilar In U.S. In 2017
This article was originally published in The Pink Sheet Daily
Executive Summary
The partners’ flexibility allows them, together and separately, to establish solid footholds in a still-evolving field with plenty of potential but also uncertainties.